TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00743080

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1
Description: Laparoscopic myomectomy with ROTOCUT G1: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (ROTOCUT G1).~Laparoscopic supracervical hysterectomy using ROTOCUT G1: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of ROTOCUT G1. Abdominal cavity irrigation.
Study: NCT02036788

Intervention type: OTHER
Intervention: Occlusion test
Description: Occlusion test to assess the correct positioning of esophageal balloon catheter when the patient is breathing spontaneously.

Intervention type: OTHER
Intervention: Thoraco-abdominal compressions
Description: Thoraco-abdominal compressions to assess the correct positioning of esophageal balloon catheter when the patient is sedated and paralyzed.
Study: NCT00625560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: entecavir 1.0 mg QD
Study: NCT01292473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was supplied lyophilized in vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied lyophilized in vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied lyophilized in vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied lyophilized in vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied lyophilized in vials.
Study: NCT05342688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-specific practice of upper extremity functions
Description: The intervention will consist of training of items from the Wolf motor function test.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task-specific practice of upper extremity functions
Description: The intervention will consist of training of items from the Wolf motor function test.
Study: NCT04354688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T3 Certain Tapered Implant
Description: Patients will be randomized to receive either the T3 Certain Tapered with DCD (Test) or the T3 Certain Tapered without DCD (control/active comparator). Both types of implants will be rehabilitated in the same manner (early loading)
Study: NCT00625560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: lamivudine 100 mg QD
Study: NCT03552003

Intervention type: OTHER
Intervention: Treatment for clinical practise
Description: Prospective data collection with the aim to to develop a prognostic index for elderly patients with newly diagnosed cHL
Study: NCT00847535

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: autologous muscle cell injection
Description: Injection of autologous muscle cells

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: autologous muscle cell injection
Description: Injection of autologous muscle cells
Study: NCT04354688

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T3 Certain Tapered Implant
Description: Patients will be randomized to receive either the T3 Certain Tapered with DCD (Test) or the T3 Certain Tapered without DCD (control/active comparator). Both types of implants will be rehabilitated in the same manner (early loading)
Study: NCT05033535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubatril Allisartan medoxomil
Description: Sacubatril Allisartan medoxomil ：A randomized, double-blind, placebo and positive drug parallel controlled, multi-center phase II clinical study on the effectiveness and safety of treating mild and moderate essential hypertension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olmesartan Medoxomil
Description: Efficacy for lowering blood pressure of Olmesartan medoxomil
Study: NCT01165736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05186462
Description: single oral administration of 100 microgram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05089771
Description: single intravenous infusion of 100 microgram of PF-05089771
Study: NCT01463579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Programme
Description: Patients will complete three exercise sessions per week (2 supervised and 1 unsupervised) for 6 weeks. They will receive a written exercise manual which facilitates completion of their exercise programme. The exercise programme will consist of a warm-up, an exercise circuit, a period of aerobic exercise, and a cool down. The programme will be tailored to each patient's ability and needs.~At the end of the 6 weeks patients will receive a short consultation to set goals relating to continuing exercise at home.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Following ICU admission patients are discharged to hospital wards to the care of a consultant, and the patients are no longer under the care of the ICU team. They are provided with appropriate medical and nursing care, and with referral to other disciplines as necessary. One mobile and able to return home to a carer or another facility they are discharged from hospital. There is usually no support to address potential problems specific to critical illness for patients after ICU discharge.
Study: NCT01188863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg LX4211 (150 mg tablets)
Description: Single oral dose of two 150 mg tablets LX4211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg LX4211 (50 mg tablets)
Description: Single oral dose of six 50 mg tablets LX4211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg LX4211 (liquid)
Description: Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)
Study: NCT01165736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05089771
Description: single oral administration of 100 microgram PF-05089771
Study: NCT01665105

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.
Study: NCT01282138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
Description: One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
Study: NCT02110277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAI/ultrasound Diagnostic Group
Description: These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
Study: NCT01282138

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)
Description: One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
Study: NCT02441257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control ventilation
Description: patients are randomly divided to receive control or spontaneous ventilation randomly.
Study: NCT04515563

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching exercise
Description: Control Group
Study: NCT02441257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spontaneous ventilation
Description: patients are randomly divided to receive control or spontaneous ventilation randomly.
Study: NCT01437761

Intervention type: DEVICE
Intervention: 2008 Sorbent System
Description: 2008 Sorbent System with dialysate flow rates (Qd) of 400 and 500 ml/min while maintaining a constant blood flow rate (Qb) and constant dialyzer (KoA).
Study: NCT06001463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSMed Dressing
Description: Half of the irradiated area was covered with CSMed® and the other half was under routine treatment. An irradiated area of 11cm\*14cm with best fit or easy accessibility was chosen for CSMed® dressing application. The area without dressing was treated with routine skin care in each patient.
Study: NCT00240032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate injection with oral cetirizine hydrochloride
Description: Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glatiramer acetate with placebo
Description: Copaxone® injection 20 mg, oral placebo
Study: NCT02949167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyHealth
Description: The MyHealth intervention is a nurse-led individually tailored symptom management program, focused on patient education and regularly collection of Patient Reported Outcomes (PRO) subsequently evaluated by specialist nurses and navigation to health care service. The nurse will meet with the patient on three-five planned appointments focused on adjustment of life after breast cancer treatment including information on symptoms of relapse or late effects and how to react on these. Close relatives are invited if patients accept. Patients will report PRO´s on symptoms of recurrence and late effects every three months during the first year and thereafter every six months.The appointments with the nurse are finalized within 3-6 month and patients will be followed with PRO for three years.
Study: NCT03865680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPP-ACP
Description: The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duraphat
Description: The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
Study: NCT05164354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Aromatherapy: It will be applied to each child three times, three days in a row. Each application will be 20 minutes. The application time will be decided together with the patient. At the end of the three-day practice.
Study: NCT04320303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: expanded NK cells
Description: Donor derived expanded NK cells were infused to patients at around days 20±3d, and 27±3d post transplantation.
Study: NCT03260738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation program with Poppy robot
Description: Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks. Among those 3 hours, patients receive 30 minutes of physical exercises dedicated to mobility of the spine supervised by robot Poppy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual rehabilitation program
Description: Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks.
Study: NCT01215539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg. Subjects with evidence of complete response, partial response or stable disease will continue to receive the combination of chemotherapy with panitumumab until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT05164354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music concert
Description: Music Concert: In this study, a music (lullaby, classical music) to be preferred by the patient or family Children are played for 20 minutes once a day. (morning or afternoon) for three days to help the child sleep. The volume of the music being played will be preserved. Aromatherapy: To be applied each child three times for three consecutive days. Each one The application will take 20 minutes. It will be time to implement The decision is made with the patient. Finally The patient's sleep quality will increase in three days of application. measured by actigraphy.
Study: NCT04471922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium enteric-coated tablet
Description: Multiple ascendinng dose, anaprazole 60mg QD(60mg QD group), 80mg QD(80mg QD group), 100mg QD(100mg QD group) , 7 days, fasting oral administration.
Study: NCT01165736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05150122
Description: single intravenous administration of 100 microgram PF-05150122
Study: NCT04471922

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose, 1 tablet QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active controlled (rabeprazole)
Description: Multiple dose, rabeprazole 20mg QD (60mg QD,80mg QD and 100mg QD group), 7 days, fasting oral administration.
Study: NCT00486187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin or sulfonylurea
Study: NCT03710629

Intervention type: OTHER
Intervention: Patients with driver genes
Description: Patients with driver genes
Study: NCT04075227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% loteprednol etabonate
Description: Use topical 0.2% loteprednol etabonate eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% dexamethasone
Description: Use topical 0.1% dexamethasone eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
Study: NCT01355432

Intervention type: OTHER
Intervention: Observation
Description: There is no intervention, this is an observational study.
Study: NCT04653415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 300mg
Description: The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone 125 mg
Description: The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tablet
Description: The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
Study: NCT02795663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS EEG HR recording
Description: NIRS EEG HR recording

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS EEG HR recording
Description: NIRS EEG HR recording

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS EEG HR recording
Description: NIRS EEG HR recording
Study: NCT00351039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Treatment Regimen Item 1: Bevacizumab 10 mg/Kg I. V. Day 1 and Day 15. Repeat cycles every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Treatment Regimen Item 2: Erlotinib 150mg Per Orally (PO) Once Daily (QD) for 7 days starting day 2 and day 15. Repeat cycles every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Treatment Regimen Item 3: Premetrexed 500mg/m2 I.V. Day 1 and Day 15. Repeat cycles every 28 days.
Study: NCT01448096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: R-CHOP21 consist of rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1.4 mg/m2, a maximum of 2mg), administered intravenously on day 1 and 100 mg oral prednisone on days 1 through 5.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic intrathecal chemotherapy
Description: Prophylactic intrathecal chemotherapy using methotrexate (12mg total dose) will be performed
Study: NCT03954808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery Training
Description: Motor imagery training will be designed for the individual basis with standard protocols
Study: NCT01359280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Counseling
Description: 5 Sessions of theory-based medication adherence counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Counseling
Description: 5 Sessions of theory-based medication adherence counseling

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Health Counseling
Description: 5 sessions of health improvement counseling

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Health Counseling
Description: 5 sessions of health improvement counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages
Description: Daily medication regimen tailored adherence reminders delivered by cell phone

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Text Messages
Description: Daily medication regimen tailored adherence reminders delivered by cell phone
Study: NCT02929121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
Study: NCT04653415

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 10 mL Injection
Description: The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
Study: NCT03891277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous succinate
Description: Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd,po during or after breakfast, Lasting for 12 weeks.~placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous succinate
Description: Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd,po during or after breakfast, Lasting for 12 weeks.~placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
Study: NCT01165736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05150122
Description: single oral administration of 100 microgram PF-05150122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05241328
Description: single intravenous infusion of 100 microgram PF-05241328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05241328
Description: single oral administration 100 microgram PF-05241328
Study: NCT02929121

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily tablet for 6 weeks: matching tablets containing no active ingredients
Study: NCT04875845

Intervention type: BEHAVIORAL
Intervention: Fasting for elective surgery
Description: 6-hours and 8-hours fasting before elective surgery

Intervention type: BEHAVIORAL
Intervention: Fasting for elective surgery
Description: 6-hours and 8-hours fasting before elective surgery
Study: NCT03473158

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ultrasound
Description: using the 6.5mHz intra-cavitary probe (65EC10EA) of ultrasound machine DP-50 (Shenzhen Mindray Bio-Medical Electronics Co., Ltd., P.R.China) to determine the number, site, size and cardiac activity of the fetuses, and monitor the fetal reduction procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ultrasound
Description: using the 6.5mHz intra-cavitary probe (65EC10EA) of ultrasound machine DP-50 (Shenzhen Mindray Bio-Medical Electronics Co., Ltd., P.R.China) to determine the number, site, size and cardiac activity of the fetuses, and monitor the fetal reduction procedure
Study: NCT02429505

Intervention type: DRUG
Intervention: Miltefosine
Description: miltefosine: target 2.5 mg/kg/day for 28 days
Study: NCT02898584

Intervention type: OTHER
Group type: OTHER
Intervention: BP Track
Study: NCT01403233

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cogniVida 50mg/day
Description: 2 capsules 25 mg (total 50 mg) cogniVida™ once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cogniVida100mg/day
Description: 4 capsules 25 mg (total 100 mg) cogniVida™ once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rebaudioside-A 303.7mg/day
Description: 4 capsules 75.92 mg (total 303.68 mg) rebaudioside A once a day
Study: NCT02985970

Intervention type: OTHER
Intervention: questionnaire
Description: The questionnaire will be send to all members of ČSARIM with the selected 4 controversial clinical scenarios in which the RSI should be used
Study: NCT03473158

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical fetal reduction
Description: under transvaginal ultrasound guidance, fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemical fetal reduction
Description: under transvaginal ultrasound guidance, fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
Study: NCT04515563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-frequency, moderate-intensity walking group
Description: once-a-week walking exercise at moderate intensity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-frequency, moderate-intensity walking group
Description: thrice-a-week walking exercise at moderate intensity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-frequency, vigorous-intensity walking group
Description: once-a-week walking exercise at vigorous intensity